DFDA

Transarterial Chemoembolization (TACE)

Treatment for Liver Cancer Due To Hepatitis B

Typical Dosage: procedure-based

Effectiveness
75%
Safety Score
35%
Clinical Trials
50
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
procedure-based
Time to Effect
1-2 months
Treatment Duration
1-3 sessions initially, repeated as needed (every 3-6 months)
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$7,000
Side Effect Mgmt:$3,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$80,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$66,667
Cost per Remission
$200,000
Comparison vs Best Supportive Care
Cost Difference
+$40,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Transarterial Chemoembolization (TACE) Outcomes

for Liver Cancer Due To Hepatitis B

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+20%
Common Side Effects
Post-embolization syndrome (pain, fever, nausea)
+80%
Liver dysfunction
+25%
Acute kidney injury
+5%
Severe complications (abscess, liver failure)
+5%

Sources:

nih.gov
mdpi.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov